Formycon Past Earnings Performance
Past criteria checks 4/6
Formycon has been growing earnings at an average annual rate of 36.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 14.3% per year. Formycon's return on equity is 15.1%, and it has net margins of 97.6%.
Key information
36.2%
Earnings growth rate
33.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 14.3% |
| Return on equity | 15.1% |
| Net Margin | 97.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/S
Jan 19
We Think Formycon (ETR:FYB) Needs To Drive Business Growth Carefully
Dec 23Formycon AG's (ETR:FYB) Share Price Not Quite Adding Up
Sep 26We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings
Nov 05We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely
Sep 04Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)
Jul 13Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates
Jun 02Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation
May 23Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation
Feb 01We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth
Sep 25We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow
May 19Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?
Jan 04
Revenue & Expenses BreakdownBeta
How Formycon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 78 | 76 | 15 | 9 |
| 30 Sep 23 | 73 | 17 | 14 | 12 |
| 30 Jun 23 | 69 | -42 | 13 | 14 |
| 31 Mar 23 | 56 | -3 | 13 | 16 |
| 31 Dec 22 | 42 | 36 | 13 | 17 |
| 30 Sep 22 | 38 | 57 | 11 | 15 |
| 30 Jun 22 | 34 | 77 | 10 | 13 |
| 31 Mar 22 | 35 | 32 | 8 | 15 |
| 31 Dec 21 | 37 | -13 | 7 | 17 |
| 30 Sep 21 | 37 | -15 | 4 | 23 |
| 30 Jun 21 | 38 | -15 | 8 | 12 |
| 31 Mar 21 | 36 | -11 | 9 | 6 |
| 31 Dec 20 | 34 | -7 | 6 | 9 |
| 30 Sep 20 | 33 | -4 | 10 | 0 |
| 30 Jun 20 | 32 | -3 | 10 | 0 |
| 31 Mar 20 | 33 | -3 | 10 | 0 |
| 31 Dec 19 | 33 | -2 | 9 | 0 |
| 30 Sep 19 | 34 | -2 | 9 | 0 |
| 30 Jun 19 | 36 | -1 | 8 | 0 |
| 31 Mar 19 | 39 | 3 | 8 | 0 |
| 31 Dec 18 | 43 | 7 | 8 | 0 |
| 30 Sep 18 | 44 | 8 | 7 | 0 |
| 30 Jun 18 | 45 | 9 | 7 | 0 |
| 31 Mar 18 | 37 | 4 | 7 | 0 |
| 31 Dec 17 | 29 | -2 | 6 | 0 |
| 30 Sep 17 | 24 | -4 | 6 | 0 |
| 30 Jun 17 | 19 | -6 | 6 | 0 |
| 31 Mar 17 | 19 | -5 | 5 | 0 |
| 31 Dec 16 | 20 | -4 | 5 | 0 |
| 30 Sep 16 | 18 | -3 | 5 | 0 |
| 30 Jun 16 | 16 | -2 | 5 | 0 |
| 31 Mar 16 | 16 | -1 | 4 | 0 |
| 31 Dec 15 | 17 | 1 | 4 | 0 |
| 30 Sep 15 | 19 | 0 | 4 | 0 |
| 30 Jun 15 | 22 | 0 | 3 | 0 |
| 31 Mar 15 | 17 | 0 | 3 | 0 |
| 31 Dec 14 | 13 | 1 | 3 | 0 |
| 31 Dec 13 | 0 | -8 | 3 | 0 |
Quality Earnings: FYB has a high level of non-cash earnings.
Growing Profit Margin: FYB's current net profit margins (97.6%) are higher than last year (84.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FYB's earnings have grown significantly by 36.2% per year over the past 5 years.
Accelerating Growth: FYB's earnings growth over the past year (110.6%) exceeds its 5-year average (36.2% per year).
Earnings vs Industry: FYB earnings growth over the past year (110.6%) exceeded the Biotechs industry -8.7%.
Return on Equity
High ROE: FYB's Return on Equity (15.1%) is considered low.